Download PDF
Previous article
Go back to website
Next article
If you have problems to see the content please click here
Other users also viewed these articles
Recommendations by the Spanish Society of Rheumatology on risk management of biological treatment and JAK inhibitors in patients with rheumatoid arthritis
Alejandro Balsa; Petra Díaz del Campo Fontecha; Lucía Silva Fernández; José Valencia Martín; Virginia Nistal Martínez; Fernando León Vázquez; M. Vanesa Hernández Hernández; Héctor Corominas; Rafael Cáliz Cáliz; José María Aguado García; Gloria Candelas Rodríguez; Nora Ibargoyen Roteta; Arturo Martí Carvajal; M. Nieves Plana Farras; Janet Puñal Riobóo; Hye Sang Park; Yolanda Triñanes Pego; Virginia Villaverde García;
Reumatol Clin. 2023;19:533-48
Systematic review of the impact of drugs on diffuse interstitial lung disease associated with rheumatoid arthritis
Carmen Carrasco Cubero; Eugenio Chamizo Carmona; Paloma Vela Casasempere;
Reumatol Clin. 2021;17:504-13
Clinical, Patient-Reported, and Ultrasound Outcomes from an Open-Label, 12-week Observational Study of Certolizumab Pegol in Spanish Patients with Rheumatoid Arthritis with or without Prior Anti-TNF Exposure
Francisco J. Blanco; Esteban Rubio-Romero; Raimon Sanmartí; César Díaz-Torné; Pablo Talavera; Jochen Dunkel; Esperanza Naredo;
Reumatol Clin. 2020;16P1:345-52